The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
REGULATORY
Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
Members of an all-important reimbursement policy panel on April 8 called for discussions on whether Japan should go ahead with its plan to implement so-called “off-year” re-pricing from next April despite the current unusual circumstances surrounding the novel coronavirus pandemic.…
To read the full story
Related Article
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
- Chuikyo Wary about Off-Year Price Survey amid COVID-19, Industry Officials Stress Concerns
May 28, 2020
- Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
- Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis
March 25, 2020
REGULATORY
- LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
May 14, 2021
- Vaccine Minister Expects Moderna Approval by May-End
May 14, 2021
- LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
May 14, 2021
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
May 14, 2021
The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…